Search research articles
Contact Us
Filters
Showing results (21-30 of 54) with videos related to
Page
of 6
Sort By:
European Journal of Haematology
|
July 18, 2013
Monoclonal gammopathy of undetermined significance: a new proposal of workup
Silvia Mangiacavalli, Federica Cocito, Lara Pochintesta, et al.
Leukemia Research
|
December 21, 2004
Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection
Alessandro Corso, Marzia Varettoni, Silvia Mangiacavalli, et al.
British Journal of Haematology
|
March 12, 2002
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis
Francesco Passamonti, Lucia Malabarba, Ester Orlandi, et al.
Cancer Medicine
|
January 10, 2014
Psychological care of caregivers, nurses and physicians: a study of a new approach
Maurizio S Abeni, Margherita Magni, Martina Conte, et al.
Haematologica
|
October 9, 2002
A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma
Alessandro Corso, Luca Arcaini, Sabrina Caberlon, et al.
American Journal of Hematology
|
December 23, 2011
Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma
Alessandro Corso, Monica Galli, Silvia Mangiacavalli, et al.
Leukemia & Lymphoma
|
June 7, 2019
Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice
Federica Cocito, Silvia Mangiacavalli, Virginia Valeria Ferretti, et al.
British Journal of Haematology
|
November 28, 2008
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
Joseph R Mikhael, Andrew R Belch, H Miles Prince, et al.
Leukemia Research
|
April 21, 2009
Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects
Alessandro Corso, Patrizia Zappasodi, Luciana Barbarano, et al.
Frontiers in Oncology
|
February 9, 2023
Experts' consensus on the definition and management of high risk multiple myeloma
Chiara Marcon, Valentina Simeon, Paola Deias, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 54) with videos related to
Sort By:
Page
of 6
European Journal of Haematology
|
July 18, 2013
Monoclonal gammopathy of undetermined significance: a new proposal of workup
Silvia Mangiacavalli, Federica Cocito, Lara Pochintesta, et al.
Leukemia Research
|
December 21, 2004
Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection
Alessandro Corso, Marzia Varettoni, Silvia Mangiacavalli, et al.
British Journal of Haematology
|
March 12, 2002
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis
Francesco Passamonti, Lucia Malabarba, Ester Orlandi, et al.
Cancer Medicine
|
January 10, 2014
Psychological care of caregivers, nurses and physicians: a study of a new approach
Maurizio S Abeni, Margherita Magni, Martina Conte, et al.
Haematologica
|
October 9, 2002
A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma
Alessandro Corso, Luca Arcaini, Sabrina Caberlon, et al.
American Journal of Hematology
|
December 23, 2011
Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma
Alessandro Corso, Monica Galli, Silvia Mangiacavalli, et al.
Leukemia & Lymphoma
|
June 7, 2019
Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice
Federica Cocito, Silvia Mangiacavalli, Virginia Valeria Ferretti, et al.
British Journal of Haematology
|
November 28, 2008
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
Joseph R Mikhael, Andrew R Belch, H Miles Prince, et al.
Leukemia Research
|
April 21, 2009
Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects
Alessandro Corso, Patrizia Zappasodi, Luciana Barbarano, et al.
Frontiers in Oncology
|
February 9, 2023
Experts' consensus on the definition and management of high risk multiple myeloma
Chiara Marcon, Valentina Simeon, Paola Deias, et al.
Page
of 6